We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 1.

Figure 1. From: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Kaplan-Meier plots. (A) Progression-free survival; R-CHOP (n=99), CHOP (n=51). (B) Overall survival; R-CHOP (n=99), CHOP (n=51). (C) Survival stratified by absolute CD4+ lymphocyte count; CD4 count > 100 R-CHOP (n=52), CD4 count > 100 CHOP (n=33), CD4 count ≥ 100 R-CHOP (n=36), CD4 ≥ 100 CHOP (n =18).

Lawrence D. Kaplan, et al. Blood. 2005 September 1;106(5):1538-1543.
2.
Figure 2.

Figure 2. From: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Immunoglobulin levels after completion of 2 cycles of chemotherapy. Levels are expressed as percent of baseline value for patients receiving R-CHOP (n=76; □); CHOP (n=31; ▪); and for those with infectious deaths that occurred after cycle 2 (n=7; ).

Lawrence D. Kaplan, et al. Blood. 2005 September 1;106(5):1538-1543.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk